Neutralization of ARCoV-induced sera against SARS-CoV-2 variants

• Κύριοι συγγραφείς: Xiao-Feng Li (Συγγραφέας), Na-Na Zhang (Συγγραφέας), Yu-Hua Li (Συγγραφέας), Shou-Chun Cao (Συγγραφέας), Yi-Fei Zhang (Συγγραφέας), Cheng-Feng Qin (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

ARCoV is a candidate mRNA vaccine encoding receptor-binding domain of SARS-CoV-2. Its safety, tolerability, and immunogenicity profile have been confirmed in the phase 1 clinical trial in China. A multi-regional phase 3 clinical trial is currently underway to test the efficacy of ARCoV (NCT04847102)...